Complement Inhibitor Eculizumab in Atypical Hemolytic Uremic Syndrome

Background and objectives: Atypical hemolytic uremic syndrome (aHUS) is associated with a congenital or acquired dysregulation of the complement alternative pathway that leads to continuous complement activation on host cells causing inflammation and damage. Eculizumab, a humanized mAb against compl...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Mache, Christoph J., Acham-Roschitz, Birgit, Frémeaux-Bacchi, Veronique, Kirschfink, Michael, Zipfel, Peter F., Roedl, Siegfried, Vester, Udo, Ring, Ekkehard
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Nephrology 2009
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2723971/
https://ncbi.nlm.nih.gov/pubmed/19556379
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2215/CJN.01090209
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller